Microdose Therapy is patient self-administration of hydrocortisone. When our patients are taught to use hydrocortisone on the bad days and not on the good ones, they use so little that hypercortisonism does not occur. Returning control to our patients not only decreases stress and fear but actually improves psychoimmunological status. It has been in widespread clinic use for 10 years for thousands of patients with no significant adverse reactions.
The United States Food and Drug Administration (FDA) has approved hydrocortisone use for endocrine disorders, rheumatic disorders, collagen diseases, dermatologic diseases, allergic states, ophthalmic diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous states, gastrointestinal diseases, and miscellaneous diseases. In accord with FDA expectations, Microdose Therapy performs with excellent efficacy:
Microdose Therapy avoids hydrocortisone-induced bone weakening
Hydrocortisone taken in high daily dosages over years causes bone weakening. Low dose hydrocortisone does not. The Mayo Clinic research staff defined the low dose upper limits to be:
Slocumb CH, Polley HF, Ward L. Diagnosis, treatment and prevention of hypercortisonism in patients with rheumatoid arthritis. Staff Meetings of the Mayo Clinic, 32(a): 227-238, 1957]
Microdose Therapy patients average using 3 mg prednisone per day (12 mg hydrocortisone per day equivalent). In agreement with the Mayo Clinic results, no significant side effects have been reported using Microdose Therapy in thousands of patients served during since 1987.
Stenberg VI, Fiechtner JJ, Rice JR, et al. Endocrine control of inflammation: rheumatoid arthritis double-blind, crossover clinical trial. Int J Clin Pharm Res. 1992; 12(1): 11-18.
Slocumb CH, Polley HF, Ward L. Diagnosis, treatment and prevention of hypercortisonism in patients with rheumatoid arthritis. Staff Meetings of the Mayo Clinic, 32(a): 227-238, 1957
One group took aspirin or phenylbutazone and the other 10 mg prednisolone per day (50 mg hydrocortisone per day equivalent). After two years and using X-ray analysis, erosion, subluxation and osteoporosis was worse in the aspirin group.
Joint Committee of the Medical Research Council and Nuffield Foundation, Ann Rheum Dis 18, 173-188, 1959
One group took 3.4 grams aspirin and the other 70 mg cortisone per day (70 mg hydrocortisone per day equivalent). After two years and using X-ray analysis, the joint erosion was more in the aspirin group than in the cortisone group.
Empire Rheumatism Council, Ann Rheum Dis 14, 353-370, 1955; 16, 777-789, 1957.
Louis A. Healey summarizes: “A low dose such as 7.5 mg prednisone per day is not cumulative and is thought to be useable indefinitely without producing osteoporosis or other serious adverse effects.”
Healey LA, Changing Therapy, Medical World News, December 12, 1988.
The United States Food and Drug Administration (FDA) has approved hydrocortisone use for endocrine disorders, rheumatic disorders, collagen diseases, dermatologic diseases, allergic states, ophthalmic diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous states, gastrointestinal diseases, and miscellaneous diseases. In accord with FDA expectations, Microdose Therapy performs with excellent efficacy:
Microdose Therapy avoids hydrocortisone-induced bone weakeningHydrocortisone taken in high daily dosages over years causes bone weakening. Low dose hydrocortisone does not. The Mayo Clinic research staff defined the low dose upper limits to be:
Slocumb CH, Polley HF, Ward L. Diagnosis, treatment and prevention of hypercortisonism in patients with rheumatoid arthritis. Staff Meetings of the Mayo Clinic, 32(a): 227-238, 1957]Microdose Therapy patients average using 3 mg prednisone per day (12 mg hydrocortisone per day equivalent). In agreement with the Mayo Clinic results, no significant side effects have been reported using Microdose Therapy in thousands of patients served during since 1987.
Stenberg VI, Fiechtner JJ, Rice JR, et al. Endocrine control of inflammation: rheumatoid arthritis double-blind, crossover clinical trial. Int J Clin Pharm Res. 1992; 12(1): 11-18.
Slocumb CH, Polley HF, Ward L. Diagnosis, treatment and prevention of hypercortisonism in patients with rheumatoid arthritis. Staff Meetings of the Mayo Clinic, 32(a): 227-238, 1957
One group took aspirin or phenylbutazone and the other 10 mg prednisolone per day (50 mg hydrocortisone per day equivalent). After two years and using X-ray analysis, erosion, subluxation and osteoporosis was worse in the aspirin group.
Joint Committee of the Medical Research Council and Nuffield Foundation, Ann Rheum Dis 18, 173-188, 1959
One group took 3.4 grams aspirin and the other 70 mg cortisone per day (70 mg hydrocortisone per day equivalent). After two years and using X-ray analysis, the joint erosion was more in the aspirin group than in the cortisone group.
Empire Rheumatism Council, Ann Rheum Dis 14, 353-370, 1955; 16, 777-789, 1957.
Louis A. Healey summarizes: “A low dose such as 7.5 mg prednisone per day is not cumulative and is thought to be useable indefinitely without producing osteoporosis or other serious adverse effects.”
Healey LA, Changing Therapy, Medical World News, December 12, 1988.
Microdose Therapy avoids hydrocortisone-induced adrenal suppression
Daily hydrocortisone administration is known to cause adrenal suppression. Microdose Therapy is scientifically designed to have 33% holidays from hydrocortisone use. During these holidays, the body’s adrenal gland hydrocortisone production is exercised to maintain production strength. In proof, Microdose patients do not use more hydrocortisone with the passage of time.
Microdose Therapy arrests joint destruction
“In patients with early, active rheumatoid arthritis, 7.5 mg prednisolone (equivalent to 37.5 mg hydrocortisone) given daily for two years substantially reduced the rate of radiologically detected progression of disease. The statistical analysis of radiologically-detected changes was based on 106 patients. After two years, the Larsen scores increased by a mean of 0.72 units in the prednisolone group indicating very little change, and by 5.37 units in the placebo group, indicating substantial joint destruction (P=0.004).”
Kirwan, JR New England Journal of Medicine, 333, 142-146, 1995.
Microdose Therapy is costs less
Microdose Therapy costs $80 a month when amortized over a 10-year basis to be one of the lowest costs medical treatments for chronic disease.
Microdose Therapy efficacy excels
Microdose Therapy excels in controlling rheumatoid arthritis:
Daily hydrocortisone administration is known to cause adrenal suppression. Microdose Therapy is scientifically designed to have 33% holidays from hydrocortisone use. During these holidays, the body’s adrenal gland hydrocortisone production is exercised to maintain production strength. In proof, Microdose patients do not use more hydrocortisone with the passage of time.
Microdose Therapy arrests joint destruction
“In patients with early, active rheumatoid arthritis, 7.5 mg prednisolone (equivalent to 37.5 mg hydrocortisone) given daily for two years substantially reduced the rate of radiologically detected progression of disease. The statistical analysis of radiologically-detected changes was based on 106 patients. After two years, the Larsen scores increased by a mean of 0.72 units in the prednisolone group indicating very little change, and by 5.37 units in the placebo group, indicating substantial joint destruction (P=0.004).”
Kirwan, JR New England Journal of Medicine, 333, 142-146, 1995.
Microdose Therapy is costs less
Microdose Therapy costs $80 a month when amortized over a 10-year basis to be one of the lowest costs medical treatments for chronic disease.
Microdose Therapy efficacy excels
Microdose Therapy excels in controlling rheumatoid arthritis:
Consider adding Microdose Therapy to your practice. You do the doctoring, we provide the technology and do the patient education.
No comments:
Post a Comment